Sang Won Jung, CEO of MVRIX , shared the development strategy for Navibody-based in vivo CAR-T at the Hankyung Bio Insight Forum 2026 held at the Lotte Hotel Jeju on the 26th.

✅ An in vivo approach in which CAR-T is produced within the body, overcoming the limitations of ex vivo (high cost/individual production)

✅ Precise Target Delivery: Enhanced target cell navigation performance upon LNP surface binding as a single-chain Navibody

✅ Expression Optimization: Designed to maintain CAR-T activity by controlling mRNA expression duration/amount using a proprietary UTR library.

Check out the article below to see how Navibody works in LNP and what achievements it aims to target by 2028.

https://www.hankyung.com/article/202602279486i